Compounds that inhibit MCL-1 protein
US12091425B2 · kind B2 · utility
0Cited by
6References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 14, 2021 |
| Grant date | Sep 17, 2024 |
| Priority date | — |
| Expiry date | Mar 12, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D515/10
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.